Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

Cell adhesion molecules, including integrins, cadherins, and claudins (CLDNs), are known to activate Src-family kinases (SFKs) that organize a variety of physiological and pathological processes; however, the underlying molecular basis remains unclear. Here, we identify the SFK members that are coupled with the CLDN6-adhesion signaling. Among SFK subtypes, BLK, FGR, HCK, and SRC were highly expressed in F9 cells and concentrated with CLDN6 along cell borders during epithelial differentiation. Immunoprecipitation assay showed that BLK and SRC, but not FGR or HCK, form a complex with CLDN6 via the C-terminal cytoplasmic domain. We also demonstrated, by pull-down assay, that recombinant BLK and SRC proteins directly bind to the C-terminal cytoplasmic domain of CLDN6 (CLDN6C). Unexpectedly, both recombinant SFK proteins recognized the CLDN6C peptide in a phosphotyrosine-independent manner. Furthermore, by comparing phenotypes of F9:Cldn6:Blk-/- and F9:Cldn6:Src-/- cells with those of wild-type F9 and F9:Cldn6 cells, we revealed that BLK and SRC are essential for CLDN6-triggered cellular events, namely epithelial differentiation and the expression of retinoid acid receptor target genes. These results indicate that selective SFK members appear to participate in the CLDN-adhesion signaling.

DOI： 10.3390/cells12131696

PubMed

researchmap

Authorship：Corresponding author   Language：English   Publishing type：Research paper (scientific journal)  

We previously identified the AKT-phosphorylation sites in nuclear receptors and showed that phosphorylation of S379 in mouse retinoic acid γ and S518 in human estrogen receptor α regulate their activity independently of the ligands. Since this site is conserved at S510 in human liver receptor homolog 1 (hLRH1), we developed a monoclonal antibody (mAb) that recognized the phosphorylation form of hLRH1S510 (hLRH1pS510) and verified its clinicopathological significance in hepatocellular carcinoma (HCC). We generated the anti-hLRH1pS510 mAb and assessed its selectivity. We then evaluated the hLRH1pS510 signals in 157 cases of HCC tissues by immunohistochemistry because LRH1 contributes to the pathogenesis of diverse cancers. The developed mAb specifically recognized hLRH1pS510 and worked for immunohistochemistry of formalin-fixed paraffin-embedded tissues. hLRH1pS510 was exclusively localized in the nucleus of HCC cells, but the signal intensity and positive rates varied among the subjects. According to the semi-quantification, 45 cases (34.9%) showed hLRH1pS510-high, and the remaining 112 cases (65.1%) exhibited hLRH1pS510-low. There were significant differences in the recurrence-free survival (RFS) between the two groups, and the 5-year RFS rates in the hLRH1pS510-high and hLRH1pS510-low groups were 26.5% and 46.1%, respectively. In addition, high hLRH1pS510 was significantly correlated with portal vein invasion, hepatic vein invasion, and high levels of serum alpha-fetoprotein (AFP). Furthermore, multivariable analysis revealed that hLRH1pS510-high was an independent biomarker for HCC recurrence. We conclude that aberrant phosphorylation of hLRH1S510 is a predictor of poor prognosis for HCC. The anti-hLRH1pS510 mAb could provide a powerful tool to validate the relevance of hLRH1pS510 in pathological processes such as tumor development and progression.

DOI： 10.1007/s10238-023-01098-x

PubMed

researchmap

Authorship：Lead author,　Corresponding author   Language：English   Publishing type：Research paper (scientific journal)  

BACKGROUND: Cell adhesion is indispensable for appropriate tissue architecture and function in multicellular organisms. Besides maintaining tissue integrity, cell adhesion molecules, including tight-junction proteins claudins (CLDNs), exhibit the signaling abilities to control a variety of physiological and pathological processes. However, it is still fragmentary how cell adhesion signaling accesses the nucleus and regulates gene expression. METHODS: By generating a number of knockout and rescued human breast cell lines and comparing their phenotypes, we determined whether and how CLDN4 affected breast cancer progression in vitro and in vivo. We also identified by RNA sequencing downstream genes whose expression was altered by CLDN4-adhesion signaling. Additionally, we analyzed by RT-qPCR the CLDN4-regulating genes by using a series of knockout and add-back cell lines. Moreover, by immunohistochemistry and semi-quantification, we verified the clinicopathological significance of CLDN4 and the nuclear receptor LXRβ (liver X receptor β) expression in breast cancer tissues from 187 patients. RESULTS: We uncovered that the CLDN4-adhesion signaling accelerated breast cancer metabolism and progression via LXRβ. The second extracellular domain and the carboxy-terminal Y197 of CLDN4 were required to activate Src-family kinases (SFKs) and the downstream AKT in breast cancer cells to promote their proliferation. Knockout and rescue experiments revealed that the CLDN4 signaling targets the AKT phosphorylation site S432 in LXRβ, leading to enhanced cell proliferation, migration, and tumor growth, as well as cholesterol homeostasis and fatty acid metabolism, in breast cancer cells. In addition, RT-qPCR analysis showed the CLDN4-regulated genes are classified into at least six groups according to distinct LXRβ- and LXRβS432-dependence. Furthermore, among triple-negative breast cancer subjects, the "CLDN4-high/LXRβ-high" and "CLDN4-low and/or LXRβ-low" groups appeared to exhibit poor outcomes and relatively favorable prognoses, respectively. CONCLUSIONS: The identification of this machinery highlights a link between cell adhesion and transcription factor signalings to promote metabolic and progressive processes of malignant tumors and possibly to coordinate diverse physiological and pathological events.

DOI： 10.1186/s13058-023-01646-z

PubMed

researchmap

Authorship：Corresponding author   Language：English   Publishing type：Research paper (scientific journal)  

The tight‑junction protein claudin‑9 (CLDN9) is barely distributed in normal adult tissues but is ectopically expressed in various cancer types. Although multiple databases indicated upregulation of CLDN9 in endometrial cancers at the mRNA level, its protein expression and biological roles remain obscure. In the present study, the prognostic significance of CLDN9 expression in endometrial cancer was evaluated by immunohistochemical staining and semi‑quantification using formalin‑fixed paraffin‑embedded specimens obtained from 248 endometrial carcinoma cases. A total of 43 cases (17.3%) had high CLDN9 expression, whereas 205 cases (82.7%) exhibited low CLDN9 expression. The 5‑year disease‑specific survival rates in the high and low CLDN9 expression groups were 62.8 and 87.8% (P<0.001), respectively. In addition, multivariate analysis revealed that high CLDN9 expression was an independent prognostic factor (hazard ratio, 4.99; 95% CI, 1.96‑12.70; P<0.001). Furthermore, CLDN9 expression was significantly correlated with the expression of CLDN6 (P<0.001), which is the closest CLDN member to CLDN9 and a poor prognostic factor for endometrial carcinoma. The 5‑year disease‑specific survival rate of cases with CLDN6‑high/CLDN9‑high, CLDN6‑high/CLDN9‑low and CLDN6‑low/CLDN9‑high status was 30.0, 37.5 and 72.7%, respectively, whereas that of CLDN6‑low/CLDN9‑low was 89.8% (P=0.004). In conclusion, aberrant CLDN9 expression is a predictor of poor prognosis for endometrial cancer and may be utilized in combination with CLDN6 to achieve higher sensitivity.

DOI： 10.3892/ijo.2022.5425

PubMed

researchmap

Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

Claudins (CLDNs) represent major transmembrane proteins of tight junctions and contribute to the barrier function. They also serve as anchors for several signaling proteins, but the underlying molecular basis has yet to be established. The present review covers the recent progress in our understanding of the CLDN signaling pathway in health and disease. We discuss the functional relevance of phosphotyrosine motifs in the C-terminal cytoplasmic domain of CLDNs and define mutual regulation between CLDNs and Src-family kinases (SFKs). In addition, we focus on the crosstalk between CLDN and transcription factor signaling. We also describe how aberrant CLDN-transcription factor signaling promotes or inhibits cancer progression. We propose that a link between various cell adhesion molecules and transcription factors coordinates a range of physiological and pathological events via activation or suppression of target genes.

DOI： 10.1080/21688370.2021.1908109

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

Cardiac regeneration requires dedifferentiation and proliferation of mature cardiomyocytes, but the mechanisms underlying this plasticity remain unclear. Here, we identify a potent cardiomyogenic role for Krüppel-like factor 1 (Klf1/Eklf), which is induced in adult zebrafish myocardium upon injury. Myocardial inhibition of Klf1 function does not affect heart development, but it severely impairs regeneration. Transient Klf1 activation is sufficient to expand mature myocardium in uninjured hearts. Klf1 directs epigenetic reprogramming of the cardiac transcription factor network, permitting coordinated cardiomyocyte dedifferentiation and proliferation. Myocardial expansion is supported by Klf1-induced rewiring of mitochondrial metabolism from oxidative respiration to anabolic pathways. Our findings establish Klf1 as a core transcriptional regulator of cardiomyocyte renewal in adult zebrafish hearts.

DOI： 10.1126/science.abe2762

PubMed

researchmap

Authorship：Lead author,　Corresponding author   Language：English   Publishing type：Research paper (scientific journal)  

BACKGROUND: Within the claudin (CLDN) family, CLDN12 mRNA expression is altered in various types of cancer, but its clinicopathological relevance has yet to be established due to the absence of specific antibodies (Abs) with broad applications. METHODS: We generated a monoclonal Ab (mAb) against human/mouse CLDN12 and verified its specificity. By performing immunohistochemical staining and semiquantification, we evaluated the relationship between CLDN12 expression and clinicopathological parameters in tissues from 138 cases of cervical cancer. RESULTS: Western blot and immunohistochemical analyses revealed that the established mAb selectively recognized the CLDN12 protein. Twenty six of the 138 cases (18.8%) showed low CLDN12 expression, and the disease-specific survival (DSS) and recurrence-free survival rates were significantly decreased compared with those in the high CLDN12 expression group. We also demonstrated, via univariable and multivariable analyses, that the low CLDN12 expression represents a significant prognostic factor for the DSS of cervical cancer patients (HR 3.412, p = 0.002 and HR 2.615, p = 0.029, respectively). CONCLUSIONS: It can be concluded that a reduced CLDN12 expression predicts a poor outcome for cervical cancer. The novel anti-CLDN12 mAb could be a valuable tool to evaluate the biological relevance of the CLDN12 expression in diverse cancer types and other diseases.

DOI： 10.3390/ijms22073774

PubMed

researchmap

Authorship：Lead author,　Corresponding author   Language：English   Publishing type：Research paper (scientific journal)  

Cell adhesion proteins not only maintain tissue integrity, but also possess signaling abilities to organize diverse cellular events in a variety of physiologic and pathologic processes; however, the underlying mechanism remains obscure. Among cell adhesion molecules, the claudin (CLDN) family is often aberrantly expressed in various cancers, but the biological relevance and molecular basis for this observation have not yet been established. Here, we show that high CLDN6 expression accelerates cellular proliferation and migration in two distinct human endometrial cancer cell lines in vitro. Using a xenograft model, we also revealed that aberrant CLDN6 expression promotes tumor growth and invasion in endometrial cancer tissues. The second extracellular domain and Y196/200 of CLDN6 were required to recruit and activate Src-family kinases (SFK) and to stimulate malignant phenotypes. Knockout and overexpression of ESR1 in endometrial carcinoma cells showed that the CLDN6-adhesion signal links to estrogen receptor α (ERα) to advance tumor progression. In particular, aberrant CLDN6-ERα signaling contributed to collective cell behaviors in the leading front of endometrial cancer cells. Importantly, we demonstrate that CLDN6/SFK/PI3K-dependent AKT and SGK (serum- and glucocorticoid-regulated kinase) signaling in endometrial cancer cells targets Ser518 in the human ERα to activate ERα transcriptional activity in a ligand-independent manner, thereby promoting tumor progression. Furthermore, CLDN6, at least in part, also regulated gene expression in an ERα-independent manner. IMPLICATIONS: The identification of this machinery highlights regulation of the transcription factors by cell adhesion to advance tumor progression.

DOI： 10.1158/1541-7786.MCR-20-0835

PubMed

researchmap

Authorship：Lead author,　Corresponding author   Language：English   Publishing type：Research paper (scientific journal)  

Junctional adhesion molecules (JAMs) are expressed in diverse types of stem and progenitor cells, but their physiological significance has yet to be established. Here, we report that JAMs exhibit a novel mode of interaction and biological activity in adipose-derived stromal/stem cells (ADSCs). Among the JAM family members, JAM-B and JAM-C were concentrated along the cell membranes of mouse ADSCs. JAM-C but not JAM-B was broadly distributed in the interstitial spaces of mouse adipose tissue. Interestingly, the JAM-C ectodomain was cleaved and secreted as a soluble form (sJAM-C) in vitro and in vivo, leading to deposition in the fat interstitial tissue. When ADSCs were grown in culture plates coated with sJAM-C, cell adhesion, cell proliferation and the expression of five mesenchymal stem cell markers, Cd44, Cd105, Cd140a, Cd166 and Sca-1, were significantly elevated. Moreover, immunoprecipitation assay showed that sJAM-C formed a complex with JAM-B. Using CRISPR/Cas9-based genome editing, we also demonstrated that sJAM-C was coupled with JAM-B to stimulate ADSC adhesion and maintenance. Together, these findings provide insight into the unique function of sJAM-C in ADSCs. We propose that JAMs contribute not only to cell-cell adhesion, but also to cell-matrix adhesion, by excising their ectodomain and functioning as a niche-like microenvironment for stem and progenitor cells.

DOI： 10.3390/biomedicines9030278

PubMed

researchmap

Authorship：Last author   Language：English   Publishing type：Research paper (scientific journal)  

The neurovascular unit (NVU) consists of neurons, glial cells, microvascular cells, and extracellular matrix, and is involved in a variety of physiological and pathological processes in the central nervous system (CNS). Within the NVU, the microvascular endothelial cells and pericytes principally contribute to maintaining the integrity of the blood-brain barrier (BBB). Various types of cells are connected to each other in the NVU by diverse cell adhesion molecules, of which claudin-5 (CLDN5) is by far the most abundantly expressed tight-junction protein in brain microvascular endothelial cells and absolutely required for the maintenance of the BBB. This review highlights recent progress in understanding the region-specific regulation and dysregulation of CLDN5 expression in CNS health and disorders. We also discuss how CLDN5 expression is regionally disrupted within the NVU. In addition, we focus on the link between cell adhesion and transcription factor signalings and describe the possible involvement of CLDN5-adhesion signaling in brain health and disorders.

DOI： 10.1002/jcp.30357

PubMed

researchmap

Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

We previously reported that site-selective claudin-5 (CLDN5) breakdown and protein kinase A (PKA) activation are observed in brain microvessels of schizophrenia, but the underlying molecular basis remains unknown. The 5-HT1 receptors decline the intracellular cAMP levels and inactivate the major downstream PKA, and the 5-HT1A receptor is a promising target for schizophrenia. Therefore, we elucidated the involvement of serotonin/5-HT1A signaling in the endothelial CLDN5 expression. We demonstrate, by immunohistochemistry using post-mortem human brain tissue, that the 5-HT1A receptor is expressed in brain microvascular endothelial cells (BMVECs) and mural cells of the normal prefrontal cortex (PFC) gray matter. We also show that PKA is aberrantly activated not only in BMVECs but also in mural cells of the schizophrenic PFC. We subsequently revealed that the endothelial cell-pericyte tube-like structure was formed in a novel two-dimensional co-culture of human primary BMVECs and a human brain-derived pericyte cell line, in both of which the 5-HT1A receptor was expressed. Furthermore, we disclose that the serotonin/5-HT1A signaling enhances endothelial CLDN5 expression in BMVECs under two-dimensional co-culture conditions. Our findings provide novel insights into the physiological and pathological significance of serotonin/5-HT1A signaling in the region-specific regulation of the blood-brain barrier.

DOI： 10.3390/ijms22010254

PubMed

researchmap

Authorship：Lead author,　Corresponding author   Language：English   Publishing type：Research paper (scientific journal)  

BACKGROUND: Among the claudin (CLDN) family, CLDN6 exhibits aberrant expression in various cancers, but its biological relevance has not yet been established. We generated a monoclonal antibody (mAb) against human CLDN6 and verified its specificity. By immunohistochemical staining and semi-quantification, we evaluated the relationship between CLDN6 expression and clinicopathological parameters in tissues from 173 cases of endometrial cancer. RESULTS: The established mAb selectively recognized CLDN6 protein. Ten of the 173 cases (5.8%) showed high CLDN6 expression (score 3+), whereas 19 (11.0%), 18 (10.4%) and 126 (72.4%) cases revealed low CLDN6 expression (score 2+, 1+ and 0, respectively). In addition, intratumor heterogeneity of CLDN6 expression was observed even in the cases with high CLDN6 expression. The 5-year survival rates in the high and low CLDN6 groups was approximately 30% and 90%, respectively. Among the clinicopathological factors, the high CLDN6 expression was significantly associated with surgical stage III/IV, histological grade 3, lymphovascular space involvement, lymph node metastasis and distant metastasis. Furthermore, the high CLDN6 expression was an independent prognostic marker for overall survival of endometrial cancer patients (hazard ratio 3.50, p = 0.014). CONCLUSIONS: It can be concluded that aberrant CLDN6 expression is useful to predict poor outcome for endometrial cancer and might be a promising therapeutic target.

DOI： 10.3390/cancers12102748

PubMed

researchmap

Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

Cell adhesion is essential for proper tissue architecture and function in multicellular organisms. Cell adhesion molecules not only maintain tissue integrity but also possess signaling properties that contribute to diverse cellular events such as cell growth, survival, differentiation, polarity, and migration; however, the underlying molecular basis remains poorly defined. Here we identify that the cell adhesion signal initiated by the tight-junction protein claudin-6 (CLDN6) regulates nuclear receptor activity. We show that CLDN6 recruits and activates Src-family kinases (SFKs) in second extracellular domain-dependent and Y196/200-dependent manners, and SFKs in turn phosphorylate CLDN6 at Y196/200. We demonstrate that the CLDN6/SFK/PI3K/AKT axis targets the AKT phosphorylation sites in the retinoic acid receptor γ (RARγ) and the estrogen receptor α (ERα) and stimulates their activities. Interestingly, these phosphorylation motifs are conserved in 14 of 48 members of human nuclear receptors. We propose that a similar link between diverse cell adhesion and nuclear receptor signalings coordinates a wide variety of physiological and pathological processes.

DOI： 10.1073/pnas.1913346116

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1016/j.devcel.2017.11.010

PubMed

Web of Science

researchmap

Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1016/j.dci.2017.03.023

PubMed

Web of Science

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1056/NEJMoa1616361

PubMed

Web of Science

researchmap

Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.7554/eLife.24635

PubMed

Web of Science

researchmap

Authorship：Corresponding author   Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1016/j.bbrc.2014.10.148

PubMed

Web of Science

researchmap

Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1371/journal.pone.0075106

PubMed

Web of Science

researchmap

Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1091/mbc.E07-09-0973

PubMed

Web of Science

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

This report describes a rare case of pneumatosis cystoides intestinalis in a dialysis patient with autosomal dominant polycystic kidney disease, detected at autopsy. Pathological findings suggest a potential link between intestinal gas cyst formation and the structural fragility associated with polycystic kidney disease.

DOI： 10.1093/omcr/omaf095

PubMed

researchmap

Language：Japanese   Publisher：(株)文光堂  

Ichushi

J-GLOBAL

researchmap

Authorship：Lead author,　Corresponding author   Language：Japanese   Publishing type：Research paper (scientific journal)  

Claudins(CLDNs)are essential components of tight junctions, which are the most apical elements of apical junctional complexes. The family consists of more than 20 members in humans and shows distinct expression patterns in a tissue- and cell-type-specific manner. Recently, many studies have shown that CLDNs overexpressed in cancer cells positively regulate their malignant behavior. First, fusion genes between CLDNs and signaling molecules produce chimeric proteins that act as drivers. Second, cancer and non-cancer cells form heterocellular adhesions via CLDNs and they act as a metastatic niche. Third, CLDNs enhance cancer cell nutrition by conjugating with amino acid transporters on the cell membrane. Fourth, CLDN acts as an activation trigger for signalling cascades. In this review, we present these 4 representative examples of how CLDNs positively regulate cancer progression.

Other Link： https://search.jamas.or.jp/default/link?pub_year=2024&ichushi_jid=J00296&link_issn=&doc_id=20241121320004&doc_link_id=%2Fab8gtkrc%2F2024%2F005111%2F004%2F1105-1110%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fab8gtkrc%2F2024%2F005111%2F004%2F1105-1110%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

PubMed

Ichushi

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

BACKGROUND: Ovarian cancer has the worst outcome among gynecological malignancies; therefore, biomarkers that could contribute to the early diagnosis and/or prognosis prediction are urgently required. In the present study, we focused on the secreted protein spondin-1 (SPON1) and clarified the prognostic relevance in ovarian cancer. METHODS: We developed a monoclonal antibody (mAb) that selectively recognizes SPON1. Using this specific mAb, we determined the expression of SPON1 protein in the normal ovary, serous tubal intraepithelial carcinoma (STIC), and ovarian cancer tissues, as well as in various normal adult tissues by immunohistochemistry, and verified its clinicopathological significance in ovarian cancer. RESULTS: The normal ovarian tissue was barely positive for SPON1, and no immunoreactive signals were detected in other healthy tissues examined, which was in good agreement with data obtained from gene expression databases. By contrast, upon semi-quantification, 22 of 242 ovarian cancer cases (9.1%) exhibited high SPON1 expression, whereas 64 (26.4%), 87 (36.0%), and 69 (28.5%) cases, which were designated as SPON1-low, possessed the moderate, weak, and negative SPON1 expression, respectively. The STIC tissues also possessed SPON1-positive signals. The 5-year recurrence-free survival (RFS) rate in the SPON1-high group (13.6%) was significantly lower than that in the SPON1-low group (51.2%). In addition, high SPON1 expression was significantly associated with several clinicopathological variables. Multivariable analysis revealed that high SPON1 was an independent prognostic factor for RFS of ovarian cancer. CONCLUSIONS: SPON1 represents a prognostic biomarker for ovarian cancer, and the anti-SPON1 mAb could be valuable as an outcome predictor.

DOI： 10.1186/s13048-023-01180-8

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

Recent studies have revealed that aberrant expression of tight junction (TJ) proteins is a hallmark of various solid tumors and it is recognized as a useful therapeutic target. Claudin-6 (CLDN6), a member of the family of TJ transmembrane proteins, is an ideal therapeutic target because it is not expressed in human adult normal tissues. In this study, we found that CLDN6 is highly expressed in uterine cervical adenocarcinoma and that high CLDN6 expression was correlated with lymph node metastasis and lymphovascular infiltration and was an independent prognostic factor. Shotgun proteome analysis revealed that cell-cell adhesion-related proteins and drug metabolism-associated proteins (aldo-keto reductase (AKR) family proteins) were significantly increased in CLDN6-overexpressing cells. Furthermore, overexpression of CLDN6 enhanced cell-cell adhesion properties and attenuated sensitivity to anticancer drugs including doxorubicin, daunorubicin and cisplatin. Taken together, the results indicate that aberrant expression of CLDN6 enhances malignant potentials and drug resistance of cervical adenocarcinoma, possibly due to increased cell-cell adhesion properties and drug metabolism. Our findings provide an insight into a new therapeutic strategy, a CLDN6-targeting therapy, against cervical adenocarcinoma.

DOI： 10.1111/cas.15284

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

The role of T cells in appendage regeneration remains unclear. In this study, we revealed an important role for regulatory T cells (Tregs), a subset of T cells that regulate tolerance and tissue repair, in the epimorphic regeneration of zebrafish caudal fin tissue. Upon amputation, fin tissue-resident Tregs infiltrate into the blastema, a population of progenitor cells that produce new fin tissues. Conditional genetic ablation of Tregs attenuates blastemal cell proliferation during fin regeneration. Blastema-infiltrating Tregs upregulate the expression of igf2a and igf2b, and pharmacological activation of IGF signaling restores blastemal proliferation in Treg-ablated zebrafish. These findings further extend our understandings of Treg function in tissue regeneration and repair.

DOI： 10.3389/fimmu.2022.981000

PubMed

researchmap

Language：English  

Anti-N-methyl-D-aspartate receptor (NMDAR) antibody encephalitis is caused by a reversible inhibition of ion channel actions by autoantibodies and is associated with a relatively good prognosis. Pathological findings of NMDAR encephalitis usually do not show neurophagorous nodules, but rare or mild inflammatory infiltration. We report a patient of small cell lung cancer (SCLC)-related paraneoplastic encephalitis with NMDAR antibodies, a cytotoxic T-cell-mediated pathology of the brain, and a rapid clinical course. This case highlights that the neuropathological diversity of NMDAR encephalitis may be even broader than previously thought and that NMDAR antibodies may also be found in various pathological conditions with a vigorous immune response.

DOI： 10.3389/fimmu.2022.952868

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

BACKGROUND: Cancer vaccines that induce endogenous antitumor immunity represent an ideal strategy to overcome intractable cancers. However, doing this against a pre-established cancer using autologous immune cells has proven to be challenging. "Allogeneic effects" refers to the induction of an endogenous immune response upon adoptive transfer of allogeneic lymphocytes without utilizing hematopoietic stem cell transplantation. While allogeneic lymphocytes have a potent ability to activate host immunity as a cell adjuvant, novel strategies that can activate endogenous antitumor activity in cancer patients remain an unmet need. In this study, we established a new method to destroy pre-developed tumors and confer potent antitumor immunity in mice using alloantigen-activated CD4+ (named AAA-CD4+) T cells. METHODS: AAA-CD4+ T cells were generated from CD4+ T cells isolated from BALB/c mice in cultures with dendritic cells (DCs) induced from C57BL/6 (B6) mice. In this culture, allogeneic CD4+ T cells that recognize and react to B6 mouse-derived alloantigens are preferentially activated. These AAA-CD4+ T cells were directly injected into the pre-established melanoma in B6 mice to assess their ability to elicit antitumor immunity in vivo. RESULTS: Upon intratumoral injection, these AAA-CD4+ T cells underwent a dramatic expansion in the tumor and secreted high levels of IFN-γ and IL-2. This was accompanied by markedly increased infiltration of host-derived CD8+ T cells, CD4+ T cells, natural killer (NK) cells, DCs, and type-1 like macrophages. Selective depletion of host CD8+ T cells, rather than NK cells, abrogated this therapeutic effect. Thus, intratumoral administration of AAA-CD4+ T cells results in a robust endogenous CD8+ T cell response that destroys pre-established melanoma. This locally induced antitumor immunity elicited systemic protection to eliminate tumors at distal sites, persisted over 6 months in vivo, and protected the animals from tumor re-challenge. Notably, the injected AAA-CD4+ T cells disappeared within 7 days and caused no adverse reactions. CONCLUSIONS: Our findings indicate that AAA-CD4+ T cells reinvigorate endogenous cytotoxic T cells to eradicate pre-established melanoma and induce long-term protective antitumor immunity. This approach can be immediately applied to patients with advanced melanoma and may have broad implications in the treatment of other types of solid tumors.

DOI： 10.1186/s13046-021-02102-6

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

Malignant mesothelioma is a cancer with a poor survival rate. It is difficult to diagnose mesotheliomas because they show a variety of histological patterns similar to those of various other cancers. However, since currently used positive markers for mesotheliomas may show false positives or false negatives, a novel mesothelial positive marker is required. In the present study, we screened 25 claudins and found that claudin-15 is expressed in the mesothelial cells. We made new rat anti-human claudin-15 (CLDN15) monoclonal antibodies that selectively recognize CLDN15, and investigated whether CLDN15 is a good positive marker for malignant pleural mesotheliomas (MPMs) using MPM tissue samples by immunohistochemistry and semi-quantification of the expression level using an immunoreactive score (IRS) method. Of 42 MPM samples, 83% were positive for CLDN15. The positive ratio was equal to or greater than other positive markers for MPMs including calretinin (81%), WT-1 (50%), and D2-40 (81%). In 50 lung adenocarcinoma sections, four cases were positive for CLDN15 and the specificity (92%) was comparable with other markers (90-100%). Notably, CLDN15 was rarely detected in 24 non-mesothelial tumors in the tissue microarray (12/327 cases). In conclusion, CLDN15 can be used in the clinical setting as a positive marker for MPM diagnosis.

DOI： 10.1038/s41598-021-91464-0

PubMed

researchmap

Authorship：Last author,　Corresponding author   Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.31662/jmaj.2020-0082

PubMed

researchmap

Language：English  

Some lactic acid bacteria (LAB) are known to improve atopic dermatitis (AD) through the regulation and stimulation of the host immune system. In this study, we found that ingestion of yogurt containing Lactococcus lactis 11/19-B1 strain (L. lactis 11/19-B1) daily for 8 weeks significantly improved the severity scoring of atopic dermatitis (SCORAD) system score from 38.8 ± 14.4 to 24.2 ± 12.0 in children suffering from AD. We tried to identify which LAB species among the five species contained in the test yogurt contributed to the improvement in AD pathology using an AD mouse model induced by repeated application of 1-fluoro-2, 4-dinitrobenzene (DNFB). AD-like skin lesions on the dorsal skin and ear were most improved by L. lactis 11/19-B1 intake among the five LAB species. In addition, analysis of CD4+ T cell subsets in Peyer's patches (PPs) and cervical lymph nodes (CLNs) indicated that the intake of L. lactis 11/19-B1 generally suppressed all subsets related to inflammation, i.e., Th1, Th2 and Th17, instead of activating the suppressive system, Treg, in the AD mouse model. Histological observations showed ingestion of L. lactis 11/19-B1 significantly suppressed severe inflammatory findings, such as inflammatory cell filtration, epidermal erosion and eosinophil infiltration. These results suggest that the immunomodulatory effects of L. lactis 11/19-B1 contribute to improvements in AD pathology.

DOI： 10.3390/nu12030763

PubMed

researchmap

Authorship：Lead author,　Corresponding author   Publishing type：Research paper (scientific journal)  

DOI： 10.1253/circj.cj-18-0669

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)   Publisher：Histology and Histopathology  

DOI： 10.14670/HH-11-949

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)   Publisher：Impact Journals LLC  

DOI： 10.18632/oncotarget.24742

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.18632/oncotarget.21850

PubMed

Web of Science

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1007/s00795-014-0074-z

PubMed

Web of Science

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1371/journal.pone.0105498

PubMed

Web of Science

researchmap

Language：Japanese   Publisher：(株)文光堂  

Ichushi

researchmap

Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1111/pin.12099

PubMed

researchmap

Language：English  

DOI： 10.1155/2011/253048

PubMed

Web of Science

researchmap

Authorship：Lead author,　Corresponding author   Language：Japanese   Publisher：(株)日本メディカルセンター  

Ichushi

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1369/jhc.6A6944.2006

PubMed

Web of Science

researchmap

Language：Japanese   Publisher：(一社)日本病理学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本病理学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本病理学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本病理学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本呼吸器外科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本小児血液・がん学会  

Ichushi

researchmap

Language：Japanese   Publisher：日本電気泳動学会  

Ichushi

researchmap

Language：Japanese   Publisher：日本電気泳動学会  

Ichushi

researchmap

Language：Japanese   Publisher：日本電気泳動学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本外科学会  

Ichushi

researchmap

Language：Japanese   Publisher：福島医学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本外科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本病理学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本病理学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本病理学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本病理学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本病理学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本病理学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本病理学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本病理学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本病理学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本病理学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本病理学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本病理学会  

Ichushi

researchmap

Language：Japanese   Publisher：日本電気泳動学会  

腫瘍組織にのみ特異的に発現する蛋白質に対し、自己免疫応答が惹起される可能性が報告されている。癌バイオマーカーとしての自己抗体は様々なプロテオミクス手法を単独または複数組み合わせて同定されている。電気泳動法と質量分析法および合成蛋白質マイクロアレイ法による自己抗体の同定について概説した。未知抗原に対する自己抗体と疾患の増悪に直接関与する自己抗体の研究を紹介し、今後の癌自己抗体研究の方向性を述べた。

Other Link:： https://search.jamas.or.jp/default/link?pub_year=2022&ichushi_jid=J06767&link_issn=&doc_id=20221019260009&doc_link_id=%2Fcp5yeido%2F2022%2F006601%2F010%2F0043-0046%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fcp5yeido%2F2022%2F006601%2F010%2F0043-0046%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本神経学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本神経学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本病理学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本病理学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本病理学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本病理学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本病理学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本病理学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本病理学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本病理学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本病理学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本病理学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本病理学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本病理学会  

Ichushi

researchmap

Language：Japanese   Publisher：日本電気泳動学会  

Ichushi

researchmap

Language：Japanese   Publisher：日本電気泳動学会  

Ichushi

researchmap

Language：Japanese   Publisher：日本電気泳動学会  

Ichushi

researchmap

Language：Japanese   Publisher：日本電気泳動学会  

Ichushi

researchmap

Language：Japanese   Publisher：日本電気泳動学会  

Ichushi

researchmap

Language：Japanese   Publisher：日本電気泳動学会  

Ichushi

researchmap

Language：Japanese   Publisher：日本電気泳動学会  

Ichushi

researchmap

Language：Japanese   Publisher：日本結合組織学会  

Ichushi

researchmap

Language：English   Publisher：(一社)日本病理学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本病理学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本病理学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本乳癌学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本外科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本外科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(NPO)日本呼吸器外科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本細胞生物学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本病理学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本病理学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本病理学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本病理学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本病理学会  

Ichushi

researchmap

Language：Japanese   Publisher：(NPO)日本肺癌学会  

Ichushi

researchmap

Language：English   Publisher：(一社)日本癌治療学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本病理学会  

Ichushi

researchmap

Language：Japanese   Publisher：(NPO)日本呼吸器外科学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本病理学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本病理学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本病理学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本乳癌学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本病理学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本病理学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本病理学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本病理学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本病理学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本病理学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本病理学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本細胞生物学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本細胞生物学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本病理学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本病理学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本病理学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本病理学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本病理学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本病理学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本病理学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本細胞生物学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本病理学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本病理学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本病理学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本病理学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本病理学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本生化学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本生化学会  

Ichushi

researchmap

Language：Japanese   Publisher：(公社)日本獣医学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本細胞生物学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本病理学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本病理学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本病理学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本病理学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本病理学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本病理学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本病理学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本病理学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本病理学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本神経学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本病理学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本病理学会  

Ichushi

researchmap

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本骨代謝学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本病理学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本病理学会  

Ichushi

researchmap

Language：Japanese   Publisher：(一社)日本病理学会  

Ichushi

researchmap

Language：English   Publishing type：Research paper, summary (international conference)  

Web of Science

researchmap

J-GLOBAL

researchmap

Event date： 2022.3

Language：Japanese  

researchmap

Event date： 2022.3

Language：Japanese  

researchmap

Event date： 2022.3

Language：Japanese  

researchmap

Event date： 2022.3

Language：Japanese  

researchmap

Event date： 2022.3

Language：Japanese  

researchmap

Event date： 2021.7

Language：Japanese  

researchmap

Event date： 2021.7

Language：Japanese  

researchmap

Event date： 2021.7

Language：Japanese  

researchmap

Event date： 2021.3

Language：English  

researchmap

Event date： 2021.3

Language：Japanese  

researchmap

Event date： 2021.3

Language：Japanese  

researchmap

Event date： 2020.10

Language：Japanese  

researchmap

Event date： 2020.8

Language：Japanese  

researchmap

Event date： 2020.8

Language：Japanese  

researchmap

Event date： 2020.8

Language：Japanese  

researchmap

Event date： 2020.6

Language：Japanese  

researchmap

Event date： 2020.3

Language：Japanese  

researchmap

Event date： 2020.3

Language：Japanese  

researchmap

Event date： 2020.3

Language：Japanese  

researchmap

Event date： 2020.3

Language：Japanese  

researchmap

Event date： 2020.3

Language：Japanese  

researchmap

Event date： 2019.11

Language：Japanese  

researchmap

Event date： 2019.10

Language：English  

researchmap

Event date： 2019.4

Language：Japanese  

researchmap

Event date： 2019.4

Language：Japanese  

researchmap

Event date： 2019.4

Language：Japanese  

researchmap

Event date： 2019.4

Language：Japanese  

researchmap

Event date： 2019.4

Language：Japanese  

researchmap

Event date： 2018.5

Language：Japanese  

researchmap

Event date： 2018.4

Language：Japanese  

researchmap

Event date： 2018.4

Language：Japanese  

researchmap

Event date： 2018.4

Language：Japanese  

researchmap

Event date： 2018.4

Language：Japanese  

researchmap

Event date： 2018.4

Language：Japanese  

researchmap

Event date： 2018.4

Language：Japanese  

researchmap

Event date： 2017.5

Language：Japanese  

researchmap

Event date： 2017.5

Language：Japanese  

researchmap

Event date： 2017.3

Language：Japanese  

researchmap

Event date： 2017.3

Language：Japanese  

researchmap

Event date： 2017.3

Language：Japanese  

researchmap

Event date： 2017.3

Language：Japanese  

researchmap

Event date： 2017.3

Language：Japanese  

researchmap

Event date： 2017.3

Language：Japanese  

researchmap

Event date： 2017.3

Language：Japanese  

researchmap

Event date： 2016.5

Language：Japanese  

researchmap

Event date： 2016.4

Language：Japanese  

researchmap

Event date： 2016.4

Language：Japanese  

researchmap

Event date： 2015.3

Language：Japanese  

researchmap

Event date： 2015.3

Language：Japanese  

researchmap

Event date： 2015.3

Language：Japanese  

researchmap

Event date： 2014.10

Language：Japanese  

researchmap

Event date： 2014.10

Language：Japanese  

researchmap

Event date： 2014.8

Language：Japanese  

researchmap

Event date： 2014.5

Language：Japanese  

researchmap

Event date： 2014.3

Language：Japanese  

researchmap

Event date： 2014.3

Language：Japanese  

researchmap

Event date： 2014.3

Language：Japanese  

researchmap

Event date： 2014.3

Language：Japanese  

researchmap

Event date： 2013.4

Language：Japanese  

researchmap

Event date： 2013.4

Language：Japanese  

researchmap

Event date： 2013.4

Language：Japanese  

researchmap

Event date： 2012.3

Language：Japanese  

researchmap

Event date： 2012.3

Language：Japanese  

researchmap

Event date： 2012.3

Language：Japanese  

researchmap

Event date： 2011.9

Language：Japanese  

researchmap

Event date： 2011.3

Language：Japanese  

researchmap

Event date： 2007.6

Language：Japanese  

researchmap

Event date： 2007.2

Language：Japanese  

researchmap

Event date： 2007.2

Language：Japanese  

researchmap

Event date： 2006.4

Language：Japanese  

researchmap

researchmap

researchmap

researchmap

researchmap

researchmap